Related Experiment Video

Updated: Jun 25, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy

Merry Y Zhao1, Aaron Auerbach, Anisha M D'Costa

  • 1Department of Pathology, University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland 21201, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 19, 2009
PubMed
Abstract

Insights

Combination therapy targeting RPS6KB1 and CDC2 shows promise for diffuse large B-cell lymphoma (DLBCL). This approach effectively inhibits DLBCL cell proliferation and overcomes drug resistance by targeting key molecular pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with significant unmet needs in refractory and recurrent cases.
  • Identifying novel molecular targets is crucial for developing effective combination chemotherapy strategies.

Purpose of the Study:

  • To identify and evaluate molecular targets for a novel combination chemotherapy for refractory and recurrent DLBCL.
  • To assess the efficacy of targeting RPS6KB1 and CDC2 in DLBCL treatment.

Main Methods:

  • Analysis of RPS6KB1 and CDC2 gene amplification and protein expression in DLBCL samples.
  • Treatment of DLBCL cell lines with rapamycin and UCN-01, alone and in combination.
  • Assessment of cell proliferation, apoptosis, and cell cycle progression following drug treatment.

Main Results:

  • RPS6KB1 and CDC2 gene amplification was observed in DLBCL.
  • High expression of phospho-p70S6K and cdc2/cdk1 proteins was found in most DLBCL cases.
  • Combination of rapamycin and UCN-01 synergistically inhibited DLBCL proliferation and induced apoptosis.

Conclusions:

  • Overexpression of RPS6KB1 and CDC2 is common in DLBCL.
  • Simultaneous targeting of phospho-p70S6K/p85S6K and cdc2/cdk1 is effective in inhibiting DLBCL proliferation and overcoming drug resistance.
  • Multilevel inhibition of the PI3K/Akt/mTOR pathway and cell cycle progression offers a promising therapeutic strategy for DLBCL.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...